Inogen Inc Stock Price, News & Analysis

Inogen (NASDAQ: INGN), a medical technology company specializing in innovative respiratory products for homecare, has scheduled its second quarter 2025 financial results announcement for August 7, 2025, after market close.

The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can access the call via US domestic line (877) 841-3961 or international line (201) 689-8589. A live webcast and replay will be available on Inogen's Investor Relations website for 6 months, with call replay accessible through August 14, 2025.

Inogen (NASDAQ: INGN) has launched Voxi 5, a new stationary oxygen concentrator designed to provide affordable and durable oxygen therapy for long-term care patients. Developed with Yuwell Medical, the device delivers 1-5 L/min of continuous flow oxygen with 87-96% concentration. Key features include quiet operation at 45dBA, compact 16.7-inch height design with lockable casters for mobility, an 8-layer internal gas pathway for medical-grade oxygen, and a 3-year sieve bed warranty for up to 8,000 hours. The Voxi 5 complements Inogen's existing At Home product line, targeting price-sensitive customers and multi-room use cases. This launch expands Inogen's market potential while utilizing existing sales channels, reinforcing their position in the home oxygen therapy market.

Inogen (NASDAQ: INGN) reported its Q1 2025 financial results, showing revenue growth of 5.5% to $82.3 million, driven by increased international and domestic B2B customer demand. The company's gross margin improved slightly to 44.2%. Operating expenses decreased by 13.1% to $44.0 million. While still reporting losses, INGN significantly reduced its GAAP net loss to $6.2 million from $14.6 million year-over-year, and adjusted net loss improved to $2.9 million. The company achieved positive adjusted EBITDA of $0.04 million, compared to negative $7.6 million in the prior year. Inogen maintains a strong balance sheet with $122.5 million in cash and no debt. For full-year 2025, the company expects revenue between $352-355 million, representing 5-6% growth, and aims to approach adjusted EBITDA breakeven.

Inogen (NASDAQ: INGN), a medical technology company specializing in innovative respiratory products for homecare, has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after market close.

The company will host a conference call the same day at 2:00 p.m. PT / 5:00 p.m. ET. Investors can join via phone using the following numbers: US domestic (877) 841-3961 and Non-US (201) 689-8589. A live audio webcast will be available through the News / Events page on Inogen's Investor Relations website, with a 6-month archive period. Call replay access will be available until May 14, 2025, via (877) 660-6853 or (201) 612-7415 with Conference ID: 13752582.

Inogen (Nasdaq: INGN), a medical technology company specializing in innovative respiratory products for homecare, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's leadership team, including President and CEO Kevin Smith and CFO Michael Bourque, will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 8:45 a.m. Eastern Time.

Interested parties can access both the live audio webcast and archived recording of the presentation through the News / Events section of Inogen's Investor Relations website. The company continues to utilize its Investor Relations website as a platform for disclosing material non-public information and maintaining compliance with Regulation FD.

Inogen (NASDAQ: INGN) reported strong financial results for Q4 and full year 2024. Q4 revenue increased 5.5% to $80.1 million, while full-year revenue grew 6.4% to $335.7 million, driven by higher international and domestic B2B sales.

Q4 gross margin improved to 45.3% from 37.1% in 2023, with operating loss narrowing to $11.4 million from $29.0 million. Full-year operating loss improved to $42.5 million from $109.4 million in 2023. The company ended 2024 with $117.4 million in cash and no debt.

For 2025, Inogen projects Q1 revenue of $79-81 million (1-4% growth) and full-year revenue of $352-355 million (5-6% growth). The company recently announced a strategic collaboration with Yuwell, including a $27.2 million equity investment giving Yuwell a 9.9% stake.

Inogen (NASDAQ: INGN) announced changes to its Board of Directors, effective January 2025. Mira Kirti Sahney has been appointed as a new board member, while Tom West will retire after serving since April 2023.

Sahney brings significant medical device industry experience, currently serving on Claria Medical's board and previously as President of Medtronic's Pelvic Health Operating Unit (2021-2024). Her experience includes roles as CEO of Hyalex Orthopaedics, leadership positions at Smith + Nephew, and co-founding Myomo. She holds multiple engineering degrees from University of Michigan and Stanford, plus an MBA from MIT.

In her new role, Sahney will join Inogen's Compliance Committee and the Nominating and Governance Committee. The appointment aims to strengthen Inogen's position as a global leader in respiratory care.

Inogen (NASDAQ: INGN) has announced a strategic collaboration with Yuwell, a global home healthcare medical device manufacturer. The partnership includes three key components: distribution of respiratory products in the US and select territories, R&D collaboration to enhance Inogen's innovation pipeline, and expansion into the Chinese market.

As part of the agreement, Yuwell will invest $27.2 million for a 9.9% equity stake in Inogen, strengthening Inogen's balance sheet. The collaboration aims to broaden Inogen's product portfolio and global presence while accelerating its growth trajectory. The collaboration agreement is effective immediately, while the equity purchase is expected to close in Q1 2025.

Inogen (NASDAQ: INGN) has announced preliminary, unaudited revenue results for Q4 and full-year 2024. The company estimates Q4 2024 revenue between $79.0-80.0 million, representing 4-5% year-over-year growth. Full-year 2024 revenue is estimated at $334.5-335.5 million, showing 6% growth and exceeding previous guidance of $329-331 million.

Performance was driven by strong double-digit growth in business-to-business revenue, while the company works on stabilizing direct-to-consumer revenue. Notable achievements include the launch of Rove 4 and FDA clearance for the SIMEOX 200 device, expanding global product offerings. The company will report official Q4 and full-year 2024 results after market close on February 25, 2025.